{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu WH"],"funding":["NCI NIH HHS"],"pagination":["e27141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3206079"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(11)"],"pubmed_abstract":["Capsomers were produced in bacteria as glutathione-S-transferase (GST) fusion proteins with human papillomavirus type 16 L1 lacking the first nine and final 29 residues (GST-HPV16L1?) alone or linked with residues 13-47 of HPV18, HPV31 and HPV45 L2 in tandem (GST-HPV16L1?-L2x3). Subcutaneous immunization of mice with GST-HPV16L1? or GST-HPV16L1?-L2x3 in alum and monophosphoryl lipid A induced similarly high titers of HPV16 neutralizing antibodies. GST-HPV16L1?-L2x3 also elicited moderate L2-specific antibody titers. Intravaginal challenge studies showed that immunization of mice with GST-HPV16 L1? or GST-HPV16L1?-L2x3 capsomers, like Cervarix®, provided complete protection against HPV16. Conversely, vaccination with GST-HPV16 L1? capsomers failed to protect against HPV18 challenge, whereas mice immunized with either GST-HPV16L1?-L2x3 capsomers or Cervarix® were each completely protected. Thus, while the L2-specific response was moderate, it did not interfere with immunity to L1 in the context of GST-HPV16L1?-L2x3 and is sufficient to mediate L2-dependent protection against an experimental vaginal challenge with HPV18."],"journal":["PloS one"],"pubmed_title":["Capsomer vaccines protect mice from vaginal challenge with human papillomavirus."],"pmcid":["PMC3206079"],"funding_grant_id":["R01 CA118790","RC2 CA148499","CA118790","R01 CA133749","P50 CA098252","CA133749"],"pubmed_authors":["Karanam B","Huh WK","Jagu S","Kwak K","Roden RB","Wu WH","Gersch E","Garcea RL"],"additional_accession":[]},"is_claimable":false,"name":"Capsomer vaccines protect mice from vaginal challenge with human papillomavirus.","description":"Capsomers were produced in bacteria as glutathione-S-transferase (GST) fusion proteins with human papillomavirus type 16 L1 lacking the first nine and final 29 residues (GST-HPV16L1?) alone or linked with residues 13-47 of HPV18, HPV31 and HPV45 L2 in tandem (GST-HPV16L1?-L2x3). Subcutaneous immunization of mice with GST-HPV16L1? or GST-HPV16L1?-L2x3 in alum and monophosphoryl lipid A induced similarly high titers of HPV16 neutralizing antibodies. GST-HPV16L1?-L2x3 also elicited moderate L2-specific antibody titers. Intravaginal challenge studies showed that immunization of mice with GST-HPV16 L1? or GST-HPV16L1?-L2x3 capsomers, like Cervarix®, provided complete protection against HPV16. Conversely, vaccination with GST-HPV16 L1? capsomers failed to protect against HPV18 challenge, whereas mice immunized with either GST-HPV16L1?-L2x3 capsomers or Cervarix® were each completely protected. Thus, while the L2-specific response was moderate, it did not interfere with immunity to L1 in the context of GST-HPV16L1?-L2x3 and is sufficient to mediate L2-dependent protection against an experimental vaginal challenge with HPV18.","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011","modification":"2021-02-19T08:26:50Z","creation":"2019-03-26T23:16:24Z"},"accession":"S-EPMC3206079","cross_references":{"pubmed":["22069498"],"doi":["10.1371/journal.pone.0027141"]}}